Professor Kerry-Anne Rye

Principal Senior Research Fellow & Professor
Medicine, Central Clinical School
Heart Research Institute

Telephone 02 8208 8900
Fax 02 9565 5584

Map

Research interests

Providing an insight into how the structure and function of high density lipoproteins protect against heart disease and other metabolic disorders

International links

Netherlands

(Amsterdam Medical Centre) Research collaboration with Dr Jan Albert Kuivenhoven and Dr Stephan Peters examining the effects of HDL on vasorelaxation

United States

(Cleveland Clinic) Research collaboraiton with Dr Stan Hazen investigating the structural organization of HDL particles.

United States

(The Scripps Research Institute) Research collaboration with Dr Linda Curtiss investigating protein conformation by surface plasmon resonance.

Selected grants

2013

  • Atherosclerosis - the key roles of HDL, cell cholesterol metabolism and vascular function; Barter P, Celermajer D, Rye K, Kritharides L, Jessup W; National Health and Medical Research Council (NHMRC)/Program Grants.

2003

  • Atherosclerosis : Lipoproteins, cell biology and vascular physiology; Stocker R, Barter P, Rye K, Barter P, Celermajer D, Jessup W, Rye K; National Health and Medical Research Council (NHMRC)/Program Grants.

2002

  • Effect of dietary fatty acid supplementation on high density lipoprotein phospholipid composition an; Nicholls S, Rye K, Celermajer D; Pfizer Australia/Cardiovascular Lipid Research Grant.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Barter, P., Rye, K. (2009). High-density lipoprotein as a therapeutic target. In Tonkin, Andrew (Eds.), Therepeutic Strategies: Lipid Disorders, (pp. 29-42). United Kingdom: Clinical Publishing, Oxford.
  • Barter, P., Rye, K. (2007). HDL and Atherosclerosis. In Christopher J Fielding (Eds.), High Density Lipoproteins: From Basic Biology to Clinical Aspects, (pp. 491-505). Germany: Wiley - V C H Verlag GmbH & Co. KGaA.
  • Barter, P., Rye, K. (2007). HDL structure and metabolism: Its regulation by cell membrane receptors. In C J Packard (Eds.), The Year in Lipid Disorders. Volume 1, (pp. 93-112). United Kingdom: Clinical Publishing, Oxford.
  • Siggins, S., Rye, K., Olkkonen, V., Jauhiainen, M., Ehnholm, C. (2007). Human plasma phospholipid transfer protein, PLTP. Structural and functional features. In Christopher J Fielding (Eds.), High Density Lipoproteins: From Basic Biology to Clinical Aspects, (pp. 183-205). Germany: Wiley - V C H Verlag GmbH & Co. KGaA.

Journals

  • Cochrane, B., Bisoendial, R., Hou, L., Glaros, E., Rossy, J., Thomas, S., Barter, P., Rye, K. (2014). Apolipoprotein a-I increases insulin secretion and production from pancreatic β-cells via a g-protein-camp-PKA-FOXO1-dependent mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(10), 2261-2267. [More Information]
  • Charlton, F., Tooher, J., Rye, K., Hennessy, A. (2014). Cardiovascular Risk, Lipids and Pregnancy: Preeclampsia and the Risk of Later Life Cardiovascular Disease. Heart, Lung and Circulation, 23(3), 203-212. [More Information]
  • Tabet, F., Vickers, K., Cuesta Torres, L., Wiese, C., Shoucri, B., Lambert, G., Catherinet, C., Prado-Lourenco, L., Levin, M., Thacker, S., Barter, P., Rye, K., et al (2014). HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nature Communications, 5, 1-14. [More Information]
  • Wu, B., Ong, K., Shrestha, S., Chen, K., Tabet, F., Barter, P., Rye, K. (2014). Inhibition of Arthritis in the Lewis Rat by Apolipoprotein A-I and Reconstituted High-Density Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(3), 543-551. [More Information]
  • Brown, B., Nobecourt, E., Zeng, J., Jenkins, A., Rye, K., Davies, M. (2013). Apolipoprotein A-I glycation by Glucose and Reactive Aldehydes Alters Phospholipid Affinity but Not Cholesterol Export from Lipid-Laden Macrophages. PLoS One, 8(5), 1-9. [More Information]
  • Ong, K., Wu, B., Cheung, B., Barter, P., Rye, K. (2013). Arthritis: Its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. Annals of Epidemiology, 23(2), 80-86. [More Information]
  • Chung, R., Kamili, A., Tandy, S., Weir, J., Gaire, R., Wong, G., Meikle, P., Cohn, J., Rye, K. (2013). Dietary Sphingomyelin Lowers Hepatic Lipid Levels and Inhibits Intestinal Cholesterol Absorption in High-Fat-Fed Mice. PLoS One, 8(2), 1-9. [More Information]
  • Rye, K. (2013). High density lipoprotein structure, function, and metabolism: a new Thematic Series. Journal of Lipid Research, 54, 2031-2033. [More Information]
  • Wu, B., Chen, K., Shrestha, S., Ong, K., Barter, P., Rye, K. (2013). High Density Lipoproteins Inhibit Vascular Endothelial Inflammation by Increasing 3[beta]-Hydroxysteroid-{Delta}24 Reductase Expression and Inducing Heme Oxygenase-1. Circulation Research, 112(2), 278-288. [More Information]
  • van der Vorst, E., Vanags, L., Dunn, L., Prosser, H., Rye, K., Bursill, C. (2013). High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells. The FASEB Journal, 27(4), 1413-1425. [More Information]
  • Mulay, V., Wood, P., Manetsch, M., Darabi, M., Cairns, R., Hoque, M., Chan, K., Reverter, M., Alvarez-Guaita, A., Rye, K., Grewal, T., et al (2013). Inhibition of Mitogen-Activated Protein Kinase Erk1/2 Promotes Protein Degradation of ATP Binding Cassette Transporters A1 and G1 in CHO and HuH7 Cells. PLoS One, 8(4), 1-10. [More Information]
  • Hadfield, K., Pattison, D., Brown, B., Hou, L., Rye, K., Davies, M., Hawkins, C. (2013). Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCI). The Biochemical Journal, 449(2), 531-542. [More Information]
  • Ong, K., Allison, M., Cheung, B., Wu, B., Barter, P., Rye, K. (2013). Trends in C-Reactive Protein Levels in US Adults From 1999 to 2010. American Journal of Epidemiology, 177(12), 1430-1442. [More Information]
  • Borthwick, F., Warnakula, S., Mangat, R., Uwiera, R., Russell, J., Kelly, S., Lee, C., Hryshko, L., Mamo, J., Rye, K., et al (2012). ApoA-1 infusion reduces arterial cholesterol and myocardial lesions in a rat model of cardiac dysfunction and insulin resistance. Atherosclerosis, 222(2), 402-408. [More Information]
  • Barter, P., Rye, K. (2012). Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. Journal of Lipid Research, 53(9), 1755-1766. [More Information]
  • Gao, X., Gu, H., Li, G., Rye, K., Zhang, D. (2012). Identification of an amino acid residue in ATP-binding cassette transport G1 critical for mediating cholesterol efflux. Biochimica et Biophysica Acta (Molecular and Cell Biology of Lipids), 1821 (3), 552-559. [More Information]
  • Ong, K., Rye, K., O'Connell, R., Jenkins, A., Brown, C., Xu, A., Sullivan, D., Barter, P., Keech, A. (2012). Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 97(12), 4701-4708. [More Information]
  • Wu, B., Chen, K., Barter, P., Rye, K. (2012). Niacin Inhibits Vascular Inflammation via the Induction of Heme Oxygenase-1. Circulation, 125(1), 150-158. [More Information]
  • Tso, C., Rye, K., Barter, P. (2012). Phenotypic and functional changes in blood monocytes following adherence to endothelium. PLoS One, 7(5), 1-11. [More Information]
  • Huijgen, R., Boekholdt, S., Arsenault, B., Bao, W., Davaine, J., Tabet, F., Petrides, F., Rye, K., DeMicco, D., Barter, P., et al (2012). Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial: A Nested Case-Control Study. Journal of the American College of Cardiology, 59(20), 1778-1784. [More Information]
  • Rye, K., Barter, P. (2012). Predictive value of different HDL particles for the protection against or risk of coronary heart disease. Biochimica et Biophysica Acta (Molecular and Cell Biology of Lipids), 1821 (3), 473-480. [More Information]
  • Barter, P., Rye, K., Beltangady, M., Ports, W., Duggan, W., Boekholdt, S., DeMicco, D., Kastelein, J., Shear, C. (2012). Relationship between atorvastatin dose and the harm caused by torcetrapib. Journal of Lipid Research, 53(11), 2436-2442. [More Information]
  • Zhang, L., Yan, F., Zhang, S., Lei, D., Charles, M., Cavigiolio, G., Oda, M., Krauss, R., Weisgraber, K., Rye, K., et al (2012). Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nature Chemical Biology, 8(4), 342-349. [More Information]
  • Drew, B., Rye, K., Duffy, S., Barter, P., Kingwell, B. (2012). The emerging role of HDL in glucose metabolism. Nature Reviews Endocrinology, 8(4), 237-245. [More Information]
  • Rye, K., Barter, P. (2012). The inhibition of cholesteryl ester transfer protein: a long and winding road. Journal of Lipid Research, 53(6), 1039-1041. [More Information]
  • Ong, K., Wu, B., Cheung, B., Barter, P., Rye, K. (2011). Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999-2008. Atherosclerosis, 219(2), 728-733. [More Information]
  • Barter, P., Rye, K. (2011). Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now? Trends In Pharmacological Sciences, 32(12), 694-699. [More Information]
  • Barter, P., Rye, K., Tardif, J., Waters, D., Boekholdt, S., Breazna, A., Kastelein, J. (2011). Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial. Circulation, 124(5), 555-562. [More Information]
  • Ong, K., Tso, A., Xu, A., Law, L., Li, M., Wat, N., Rye, K., Lam, T., Cheung, B., Lam, K. (2011). Evaluation of the combined use of adiponectin and C-reactive protein levels as biomarkers for predicting the deterioration in glycaemia after a median of 5.4 years. Diabetologia: clinical and experimental diabetes and metabolism, 54(10), 2552-2560. [More Information]
  • Reimers, G., Jackson, C., Rickards, J., Chan, P., Cohn, J., Rye, K., Barter, P., Rodgers, K. (2011). Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I. Cardiovascular Research, 91(1), 37-44. [More Information]
  • Elliott, D., Tsoi, K., Holinkova, S., Chan, S., Kim, W., Halliday, G., Rye, K., Garner, B. (2011). Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiology of Aging: age-related phenomena, neurodegeneration and neuropathology, 32(2), 257-271. [More Information]
  • Tabet, F., Lambert, G., Torres, L., Hou, L., Sotirchos, I., Touyz, R., Jenkins, A., Barter, P., Rye, K. (2011). Lipid-Free Apolipoprotein A-I and Discoidal Reconstituted High-Density Lipoproteins Differentially Inhibit Glucose-Induced Oxidative Stress in Human Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(5), 1192-1200. [More Information]
  • Zhang, L., Song, J., Cavigiolio, G., Ishida, B., Zhang, S., Kane, J., Weisgraber, K., Oda, M., Rye, K., Pownall, H., et al (2011). Morphology and structure of lipoproteins revealed by an optimized negative-staining protocol of electron microscopy. Journal of Lipid Research, 52(1), 175-184. [More Information]
  • Kitajima, K., Miura, S., Yamauchi, T., Uehara, Y., Kiya, Y., Rye, K., Kadowaki, T., Saku, K. (2011). Possibility of increasing cholesterol efflux by adiponectin and its receptors through the ATP binding cassette transporter A1 in HEK293T cells. Biochemical and Biophysical Research Communications, 411(2), 305-311. [More Information]
  • Wood, P., Mulay, V., Darabi, M., Chan, K., Heeren, J., Pol, A., Lambert, G., Rye, K., Enrich, C., Grewal, T. (2011). RAS/Mitogen-activated Protein Kinase (MAPK) Signalling Modulates Protein Stability and Cell Surface Expression of Scavenger Receptor SR-BI. Journal of Biological Chemistry, 286(26), 23077-23092. [More Information]
  • Di Bartolo, B., Nicholls, S., Bao, B., Rye, K., Heather, A., Barter, P., Bursill, C. (2011). The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Atherosclerosis, 217(2), 395-400. [More Information]
  • Di Bartolo, B., Vanags, L., Tan, J., Bao, B., Rye, K., Barter, P., Bursill, C. (2011). The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit. Lipids in Health and Disease, 10(NOvember), Article no. 224-(8pp). [More Information]
  • Wu, Z., Gogonea, V., Lee, X., May, R., Pipich, V., Wagner, M., Undurti, A., Tallant, T., Baleanu-Gogonea, C., Charlton, F., Rye, K., et al (2011). The Low Resolution Structure of ApoA1 in Spherical High Density Lipoprotein Revealed by Small Angle Neutron Scattering. Journal of Biological Chemistry, 286(14), 12495-12508. [More Information]
  • Patel, S., Di Bartolo, B., Nakhla, S., Heather, A., Mitchell, T., Jessup, W., Celermajer, D., Barter, P., Rye, K. (2010). Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis, 212(2), 392-397. [More Information]
  • Fryirs, M., Barter, P., Appavoo, M., Tuch, B., Tabet, F., Heather, A., Rye, K. (2010). Effects of High-Density Lipoproteins on Pancreatic {beta}-Cell Insulin Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(8), 1642-1648. [More Information]
  • Wu, B., Yan, L., Charlton, F., Witting, P., Barter, P., Rye, K. (2010). Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(5), 968-975. [More Information]
  • Chan, D., Hamilton, S., Rye, K., Chew, G., Jenkins, A., Lambert, G., Watts, G. (2010). Fenofibrate Concomitantly Decreases Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Very-Low-Density Lipoprotein Particle Concentrations in Statin-treated Type 2 Diabetic Patients. Diabetes, Obesity and Metabolism, 12(9), 752-756. [More Information]
  • Bursill, C., Castro, M., Beattie, D., Nakhla, S., van der Vorst, E., Heather, A., Barter, P., Rye, K. (2010). High-Density Lipoproteins Suppress Chemokines and Chemokine Receptors In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(9), 1773-1778. [More Information]
  • Nobecourt, E., Tabet, F., Lambert, G., Puranik, R., Bao, B., Yan, L., Davies, M., Brown, B., Jenkins, A., Dusting, G., Barter, P., Rye, K., et al (2010). Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(4), 766-772. [More Information]
  • Imaizumi, S., Kiya, Y., Miura, S., Zhang, B., Matsuo, Y., Uehara, Y., Rye, K., Saku, K. (2010). Pharmacological intervention using reconstituted high-density lipoprotein changes in the lipid profile in spontaneously hypersensitive rats. Clinical and Experimental Hypertension, 32(3), 202-208. [More Information]
  • de Souza, J., Vindis, C., Negre-Salvayre, A., Rye, K., Couturier, M., Therond, P., Chantepie, S., Salvayre, R., Chapman, M., Kontush, A. (2010). Small, dense HDL3 particles attenuates apoptosis in endothelial cells: Pivotal role of apolipoprotein A-I. Journal of Cellular and Molecular Medicine, 14(3), 608-620. [More Information]
  • Tabet, F., Remaley, A., Segaliny, A., Millet, J., Yan, L., Nakhla, S., Barter, P., Rye, K., Lambert, G. (2010). The 5A Apolipoprotein A-I Mimetic Peptide Displays Antiinflammatory and Antioxidant Properties In Vivo and In Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(2), 246-252. [More Information]
  • Patel, S., Puranik, R., Nakhla, S., Lundmand, P., Stocker, R., Wang, X., Lambert, G., Rye, K., Barter, P., Nicholls, S., Celermajer, D. (2009). Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis, 204(2), 424-428. [More Information]
  • Fryirs, M., Barter, P., Rye, K. (2009). Cholesterol metabolism and pancreatic B-cell function. Current Opinion in Lipidology, 20(3), 159-164. [More Information]
  • Tabet, F., Rye, K. (2009). High-density lipoproteins, inflammation and oxidative stress. Clinical Science, 116(2), 87-98. [More Information]
  • Lambert, G., Charlton, F., Rye, K., Piper, D. (2009). Molecular basis of PCSK9 function. Atherosclerosis, 203, 1-7. [More Information]
  • Chan, D., Lambert, G., Barrett, P., Rye, K., Ooi, E., Watts, G. (2009). Plasma proprotein convertase subtilisin/kexin type 9: A marker of LDL apolipoprotein B-100 catabolism? Clinical Chemistry (Washington, DC), 55(11), 2049-2052. [More Information]
  • Kiya, Y., Miura, S., Imaizumi, S., Uehara, Y., Matsuo, Y., Abe, S., Jimi, S., Urata, H., Rye, K., Saku, K. (2009). Reconstituted high-density lipoprotein attenuates postinfarction left ventricular remodeling in rats. Atherosclerosis, 203(1), 137-144. [More Information]
  • Patel, S., Drew, B., Nakhla, S., Duffy, S., Murphy, A., Barter, P., Rye, K., Chin-Dusting, J., Hoang, A., Sviridov, D., Celermajer, D., et al (2009). Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. Journal of the American College of Cardiology, 53(11), 962-971. [More Information]
  • Peshavariya, H., Dusting, G., Di Bartolo, B., Rye, K., Barter, P., Jiang, F. (2009). Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free Radical Research, 43(8), 772-782. [More Information]
  • Chan, D., Watts, G., Ooi, E., Rye, K., Ji, J., Johnson, A., Barrett, P. (2009). Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome. Diabetes Care, 32(11), 2111-2113. [More Information]
  • McGrath, K., Li, X., Puranik, R., Liong, E., Tan, J., Dy, V., Di Bartolo, B., Barter, P., Rye, K., Heather, A. (2009). Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 877-882. [More Information]
  • Rye, K., Bursill, C., Lambert, G., Tabet, F., Barter, P. (2009). The metabolism and anti-atherogenic properties of HDL. Journal of Lipid Research, 50(Supplement), S195-S200. [More Information]
  • Kim, W., Elliott, D., Kockx, M., Kritharides, L., Rye, K., Jans, D., Garner, B. (2008). Analysis of apolipoprotein E nuclear localization using green fluorescent protein and biotinylation approaches. Biochemical Journal, 409(3), 701-709. [More Information]
  • Rye, K., Barter, P. (2008). Antiinflammatory Actions of HDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(11), 1890-1891. [More Information]
  • Tabet, F., Barter, P., Rye, K. (2008). Apolipoprotein A-I and Reconstituted High-Density Lipoproteins Inhibit NADPH Oxidase Activation and Expression and Increase Superoxide Dismutase Levels in Human Macrophages in High Glucose Conditions. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(6), e-87.
  • Chan, S., Kim, W., Kwok, J., Hill, A., Cappai, R., Rye, K., Garner, B. (2008). ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. Journal of Neurochemistry, 106(2), 793-804. [More Information]
  • Nobécourt, E., Zeng, J., Davies, M., Bronwyn, B., Yadav, S., Barter, P., Rye, K. (2008). Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I. Diabetologia: clinical and experimental diabetes and metabolism, 51(6), 1008-1017. [More Information]
  • Homer, V., Marais, A., Charlton, F., Laurie, A., Hurndell, N., Scott, R., Mangili, F., Sullivan, D., Barter, P., Rye, K., et al (2008). Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis, 196(2), 659-666. [More Information]
  • Di Bartolo, B., Bao, B., Rye, K., Nicholls, S., Barter, P. (2008). In Vivo Properties of a Novel Apolipoprotein A-1 Mimetic Peptide. Journal of the American College of Cardiology, 51(10), A283.
  • Barter, P., Rye, K. (2008). Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome? Arteriosclerosis, Thrombosis, and Vascular Biology, 28(1), 39-46. [More Information]
  • Puranik, R., Bao, B., Nobecourt, E., Nicholls, S., Dusting, G., Barter, P., Celermajer, D., Rye, K. (2008). Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis, 196(1), 240-247. [More Information]
  • Glaros, E., Kim, W., Quinn, C., Jessup, W., Rye, K., Garner, B. (2008). Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. Journal of Lipid Research, 49(2), 324-331. [More Information]
  • Lambert, G., Ancellin, N., Charlton, F., Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D., Cohn, J., Rye, K., Barter, P. (2008). Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment. Clinical Chemistry (Washington, DC), 54(6), 1038-1045. [More Information]
  • Uehara, Y., Tsuboi, Y., Zhang, B., Miura, S., Baba, Y., Higuchi, M., Yamada, T., Rye, K., Saku, K. (2008). POPC/apoA-I discs as a potent lipoprotein modulator in Tangier disease. Atherosclerosis, 197(1), 283-289. [More Information]
  • Glaros, E., Kim, W., Rye, K., Shayman, J., Garner, B. (2008). Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice. Journal of Lipid Research, 49(8), 1677-1681. [More Information]
  • Settasatian, N., Barter, P., Rye, K. (2008). Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein. Journal of Lipid Research, 49(1), 115-126. [More Information]
  • D. Silva, R., Huang, R., Morris, J., Fang, J., Gracheva, E., Ren, G., Kontush, A., Jerome, W., Rye, K., Davidson, W. (2008). Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 105(34), 12176-12181.
  • Patel, S., Drew, B., Duffy, S., Nahkla, S., Rye, K., Barter, P., Celermajer, D., Kingwell, B. (2007). Abstract 1047: Infusion of Reconstituted High Density Lipoproteins Into Humans Enhances the In Vitro Anti-Inflammatory Capacity of the High Density Lipoprotein Fraction. Circulation, 116, II_209.
  • Theodore, W., Watts, G., Barrett, P., Rye, K., Chan, D. (2007). Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care, 30(11), 2945-2950. [More Information]
  • Zhang, B., Uehara, Y., Hida, S., Miura, S., Rainwater, D., Segawa, M., Kumagai, K., Rye, K., Saku, K. (2007). Effects of reconstituted HDL on charge-based LDL subfractions as characterized by capillary isotachophoresis. Journal of Lipid Research, 48, 1175-1189. [More Information]
  • Homer, V., Marais, A., Laurie, A., Charlton, F., Sullivan, D., Barter, P., Rye, K., George, P., Lambert, G. (2007). Identification and Molecular Characterization of New PCSK9 Missense Mutations Associated with Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(6), e-122.
  • Glaros, E., Kim, W., Wu, B., Suarna, C., Quinn, C., Rye, K., Stocker, R., Jessup, W., Garner, B. (2007). Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochemical Pharmacology, 73(9), 1340-1346. [More Information]
  • Skropeta, D., Settasatian, C., McMahon, M., Shearston, K., Caiazza, D., McGrath, K., Jin, W., Rader, D., Barter, P., Rye, K. (2007). N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins. Journal of Lipid Research, 48(9), 2047-2057. [More Information]
  • Barter, P., Puranik, R., Rye, K. (2007). New insights into the role of HDL as an antiinflammatory agent in the prevention of cardiovascular disease. Current Cardiology Reports, 9(6), 493-498. [More Information]
  • Matsuo, Y., Miura, S., Kawamura, A., Uehara, Y., Rye, K., Saku, K. (2007). Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation. Atherosclerosis, 194, 159-168. [More Information]
  • Sumi, M., Sata, M., Miura, S., Rye, K., Toya, N., Kanaoka, Y., Yanaga, K., Ohki, T., Saku, K., Nagai, R. (2007). Reconstituted High-Density Lipoprotein Stimulates Differentiation of Endothelial Progenitor Cells and Enhances Ischemia-Induced Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(4), 813-818. [More Information]
  • Nobecourt, E., Davies, M., Brown, B., Curtiss, L., Bonnet, D., Charlton, F., Januszewski, A., Jenkins, A., Barter, P., Rye, K. (2007). The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia: clinical and experimental diabetes and metabolism, 50(3), 643-653. [More Information]
  • Puranik, R., Bao, B., Celermajer, D., Rye, K., Barter, P., Nicholls, S., Nobecourt, E. (2006). A single infusion of lipid free apo A1 can rescue vascular inflammation. Atherosclerosis Supplements, 7, 153.
  • Gelissen, I., Harris, M., Quinn, C., Rye, K., Brown, A., Kockx, M., Cartland, S., Packianathan, M., Kritharides, L., Jessup, W. (2006). ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(3), 534-540. [More Information]
  • Puranik, R., Nobecourt, E., Bao, B., Davies, M., Barter, P., Celermajer, D., Rye, K. (2006). Abstract 1355: The Impact of Glycation on the Anti-inflammatory Properties of High Density Lipoproteins in vivo. Circulation, 114, II-257-II-258.
  • Barter, P., Rye, K. (2006). Are we lowering LDL cholesterol sufficiently? Nature Clinical Practice Cardiovascular Medicine, 3(6), 290-291. [More Information]
  • Barter, P., Rye, K. (2006). Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism? Circulation, 113(12), 1553-1555.
  • Teo, K., Nicholls, S., Kee, P., Rye, K., Barter, P. (2006). Combination high-density lipoprotein infusion and atorvastatin significantly reduces experimental atherosclerosis compared to either therapy alone: serial analysis with high-resolution MRI. European Heart Journal, 27(Suppl 1), 973-974.
  • Nicholls, S., Lundman, P., Harmer, J., Cutri, B., Griffiths, K., Rye, K., Barter, P., Celermajer, D. (2006). Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. Journal of the American College of Cardiology, 48(4), 715-720. [More Information]
  • Zhang, B., Katafuchi, R., Arishima, H., Matsunaga, A., Rye, K., Saku, K. (2006). Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis. Clinica Chimica Acta, 373(1-2), 55-61.
  • Hime, N., Drew, K., Wee, K., Barter, P., Rye, K. (2006). Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit. Journal of Lipid Research, 47(1), 115-122. [More Information]
  • Rye, K., Barter, P., Bao, B. (2006). HDL and the inhibition of inflammation in vivo. Atherosclerosis Supplements, 7, 152.
  • Ji, J., Watts, G., Johnson, A., Chan, D., Ooi, E., Rye, K., Serone, A., Barrett, P. (2006). High-density lipoprotein (HDL) transport in the metabolic syndrome: Application of a new model for HDL particle kinetics. Journal of Clinical Endocrinology and Metabolism, 91(3), 973-979. [More Information]
  • Tso, C., Martinic, G., Fan, W., Rogers, C., Rye, K., Barter, P. (2006). High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(5), 1144-1149. [More Information]
  • Barter, P., Rye, K. (2006). Homocysteine and Cardiovascular Disease: Is HDL the Link? Circulation Research, 99(6), 565-566.
  • Rentero, C., Evans, R., Wood, P., Tebar, F., Vila de Muga, S., Cubells, L., de Diego, I., Hayes, T., Hughes, W., Pol, A., Rye, K., Grewal, T., et al (2006). Inhibition of H-Ras and MAPK is compensated by PKC-dependent pathways in annexin A6 expressing cells. Cellular Signalling, 18(7), 1006-1016. [More Information]
  • Ooi, E., Watts, G., Ji, J., Rye, K., Johnson, A., Chan, D., Barrett, P. (2006). Plasma phospholipid transfer protein activity, a determinant of HDL kinetics in vivo. Clinical Endocrinology, 65(6), 752-759.
  • Rye, K., Bright, R., Psaltis, M., Barter, P. (2006). Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E. Journal of Lipid Research, 47(5), 1025-1036. [More Information]
  • Barter, P., Rye, K. (2006). Relationship between the concentration and antiatherogenic activity of high-density lipoproteins. Current Opinion in Lipidology, 17(4), 399-403. [More Information]
  • Watts, G., Ji, J., Chan, D., Ooi, E., Johnson, A., Rye, K., Barrett, P. (2006). Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. Clinical Science, 111(3), 193-199.
  • Kim, W., Rahmanto, A., Kamili, A., Rye, K., Guillemin, G., Gelissen, I., Jessup, W., Hill, A., Garner, B. (2006). Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein-E discs and suppression of amyloid-beta peptide generation. Journal of Biological Chemistry, 282(5), 2851-2861. [More Information]
  • Barter, P., Rye, K. (2006). The Argument Against the Appropriateness of Over-the-Counter Statins. Circulation, 114(12), 1315-1320. [More Information]
  • Rye, K., Nobecourt, E., Puranik, R., Bao, B., Barter, P. (2006). The impact of diabetes on the anti-inflammatory properties of high density lipoproteins in vivo. European Heart Journal, 27(Suppl 1), 520.
  • Barter, P., Rye, K. (2006). The rationale for using apoA-I as a clinical marker of cardiovascular risk. Journal of Internal Medicine, 259(5), 447-454. [More Information]
  • Curtiss, L., Valenta, D., Hime, N., Rye, K. (2006). What is so special about apolipoprotein AI in reverse cholesterol transport? Arteriosclerosis, Thrombosis, and Vascular Biology, 26(1), 12-19.
  • Grewal, T., Evans, R., Rentero, C., Tebar, F., Cubells, L., de Diego, I., Kirchhoff, M., Hughes, W., Heeren, J., Rye, K., et al (2005). Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity. Oncogene, 24(38), 5809-5820. [More Information]
  • Zhang, B., Miura, S., Fan, P., Kumagai, K., Takeuchi, K., Uehara, Y., McMahon, M., Rye, K., Saku, K. (2005). ApoA-I/phosphatidylcholine discs remodels fast-migrating HDL into slow-migrating HDL as characterized by capillary isotachophoresis. Atherosclerosis, 188(1), 95-101. [More Information]
  • Janis, M., Metso, J., Lankinen, H., Strandin, T., Olkkonen, V., Rye, K., Jauhiainen, M., Ehnholm, C. (2005). Apolipoprotein E activates the low-activity form of human phospholipid transfer protein. Biochemical and Biophysical Research Communications, 331(1), 333-340. [More Information]
  • Nicholls, S., Celermajer, D., Rye, K., Barter, P., Griffiths, K., Cutri, B., Harmer, J., Lundman, P. (2005). Consumption of saturated fat impairs endothelial function and the antiinflammatory properties of high-density lipoproteins. Circulation, 112(17), U43.
  • Kee, P., Caiazza, D., Rye, K., Barrett, P., Morehouse, L., Barter, P. (2005). Effect of Inhibiting Cholesteryl Ester Transfer Protein on the Kinetics of High-Density Lipoprotein Cholesteryl Ester Transport in Plasma: In Vivo Studies in Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(4), 884-890. [More Information]
  • Jahangiri, A., Rader, D., Marchadier, D., Curtiss, L., Bonnet, D., Rye, K. (2005). Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. Journal of Lipid Research, 46(5), 896-903.
  • Nicholls, S., Rye, K., Barter, P. (2005). High-density lipoproteins as therapeutic targets. Current Opinion in Lipidology, 16(3), 345-349. [More Information]
  • Nicholls, S., Cutri, B., Worthley, S., Kee, P., Rye, K., Bao, B., Barter, P. (2005). Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(11), 2416-2421. [More Information]
  • Raftery, M., Campbell, R., Glaros, E., Rye, K., Halliday, G., Jessup, W., Garner, B. (2005). Phosphorylation of Apolipoprotein-E at an Atypical Protein Kinase CK2 PSD/E Site in Vitro. Biochemistry, 44(19), 7346-7353. [More Information]
  • Nicholls, S., Dusting, G., Cutri, B., Bao, B., Drummond, G., Rye, K., Barter, P. (2005). Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation, 111(12), 1543-1550. [More Information]
  • Settasatian, N., Barter, P., Rye, K. (2005). The Influence of Apolipoprotein E Isoforms on High Density Lipoprotein Remodelling by Phospholipid Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(5), E-90.
  • Settasatian, C., van der Meer, A., Rader, D., Barter, P., Rye, K. (2005). The Role of the Beta5 Loop of Endothelial Lipase in the Hydrolysis of Reconstituted High-Density Lipoprotein Phospholipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(5), E-76.
  • Barter, P., Nicholls, S., Rye, K., Anantharamaiah, G., Navab, M., Fogelman, A. (2004). Antiinflammatory Properties Of HDL. Circulation Research, 95(8), 764-772. [More Information]
  • Kockx, M., Rye, K., Gaus, K., Quinn, C., Wright, J., Sloane, T., Sviridov, D., Sullivan, D., Fu, Y., Burnett, J., Kritharides, L., et al (2004). Apolipoprotein A-I-Stimulated Apolipoprotein E Secretion From Human Macrophages Is Independent Of Cholesterol Efflux. Journal of Biological Chemistry, 279(25), 25966-25977.
  • Hime, N., Drew, K., Hahn, C., Barter, P., Rye, K. (2004). Apolipoprotein E Enhances Hepatic Lipase-Mediated Hydrolysis of Reconstituted High-Density Lipoprotein Phospholipid and Triacylglycerol in an Isoform-Dependent Manner. Biochemistry, 43(38), 12306-12314.
  • Hime, N., Drew, K., Hahn, C., Barter, P., Rye, K. (2004). Apolipoprotein E Enhances Hepatic Lipase-Mediated Hydrolysis Of Reconstituted High-Density Lipoprotein Phospholipid And Triacylglycerol In An Isoform-Dependent Manner. Biochemistry, 43(38), 12306-12314.
  • Caiazza, D., Jahangiri, A., Rader, D., Marchadier, D., Rye, K. (2004). Apolipoproteins Regulate The Kinetics Of Endothelial Lipase-Mediated Hydrolysis Of Phospholipids In Reconstituted High-Density Lipoproteins. Biochemistry, 43(37), 11898-11905.
  • Rye, K., Barter, P. (2004). Formation And Metabolism Of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(3), 421-428. [More Information]
  • Wadham, C., Albanese, N., Roberts, J., Wang, L., Bagley, C., Gamble, J., Rye, K., Barter, P., Vadas, M., Xia, P. (2004). High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity. Circulation, 109(17), 2116-2122. [More Information]
  • Heeren, J., Grewal, T., Laatsch, A., Becker, N., Rinninger, F., Rye, K., Beisiegel, U. (2004). Impaired Recycling of Apolipoprotein E4 Is Associated with Intracellular Cholesterol Accumulation. Journal of Biological Chemistry, 279(53), 55483-55492. [More Information]
  • Hime, N., Drew, K., Barter, P., Rye, K. (2004). In Vivo Formation of High-Density Lipoproteins Containing Both Apolipoprotein A-I and Apolipoprotein A-II in the Rabbit. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(5), E-104.
  • Duong, M., Psaltis, M., Rader, D., Marchadier, D., Barter, P., Rye, K. (2003). Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids. Biochemistry, 42(46), 13778-13785. [More Information]
  • Rye, K., Duong, M., Psaltis, M., Curtiss, L., Bonnet, D., Stocker, R., Barter, P. (2002). Evidence that phospholipids play a key role in pre-β apoA-I formation and high density lipoprotein remodeling. Biochemistry, 41(41), 12538-12545.
  • Panzenboeck, U., Kritharides, L., Raftery, M., Rye, K., Stocker, R. (2000). Oxidation of methionine residues to methionine sulfoxides enhances rather than decreases potential anti-atherogenic properties of apolipoprotein. Journal of Biological Chemistry, 275, 19536-19544.

Conferences

  • Nobecourt, E., Puranik, R., Bao, B., Davies, M., Barter, P., Rye, K. (2006). Evidence that glycation of apolipoprotein. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Taylor, J., Rye, K., Sloane, T., Gaus, K., Ruberu, K., Jessup, W., Kritharides, L. (2006). Exogenous apolipoprotein A-I promotes faecal sterol excretion in hypercholesterolemic rabbits. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.

2014

  • Cochrane, B., Bisoendial, R., Hou, L., Glaros, E., Rossy, J., Thomas, S., Barter, P., Rye, K. (2014). Apolipoprotein a-I increases insulin secretion and production from pancreatic β-cells via a g-protein-camp-PKA-FOXO1-dependent mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(10), 2261-2267. [More Information]
  • Charlton, F., Tooher, J., Rye, K., Hennessy, A. (2014). Cardiovascular Risk, Lipids and Pregnancy: Preeclampsia and the Risk of Later Life Cardiovascular Disease. Heart, Lung and Circulation, 23(3), 203-212. [More Information]
  • Tabet, F., Vickers, K., Cuesta Torres, L., Wiese, C., Shoucri, B., Lambert, G., Catherinet, C., Prado-Lourenco, L., Levin, M., Thacker, S., Barter, P., Rye, K., et al (2014). HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nature Communications, 5, 1-14. [More Information]
  • Wu, B., Ong, K., Shrestha, S., Chen, K., Tabet, F., Barter, P., Rye, K. (2014). Inhibition of Arthritis in the Lewis Rat by Apolipoprotein A-I and Reconstituted High-Density Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(3), 543-551. [More Information]

2013

  • Brown, B., Nobecourt, E., Zeng, J., Jenkins, A., Rye, K., Davies, M. (2013). Apolipoprotein A-I glycation by Glucose and Reactive Aldehydes Alters Phospholipid Affinity but Not Cholesterol Export from Lipid-Laden Macrophages. PLoS One, 8(5), 1-9. [More Information]
  • Ong, K., Wu, B., Cheung, B., Barter, P., Rye, K. (2013). Arthritis: Its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. Annals of Epidemiology, 23(2), 80-86. [More Information]
  • Chung, R., Kamili, A., Tandy, S., Weir, J., Gaire, R., Wong, G., Meikle, P., Cohn, J., Rye, K. (2013). Dietary Sphingomyelin Lowers Hepatic Lipid Levels and Inhibits Intestinal Cholesterol Absorption in High-Fat-Fed Mice. PLoS One, 8(2), 1-9. [More Information]
  • Rye, K. (2013). High density lipoprotein structure, function, and metabolism: a new Thematic Series. Journal of Lipid Research, 54, 2031-2033. [More Information]
  • Wu, B., Chen, K., Shrestha, S., Ong, K., Barter, P., Rye, K. (2013). High Density Lipoproteins Inhibit Vascular Endothelial Inflammation by Increasing 3[beta]-Hydroxysteroid-{Delta}24 Reductase Expression and Inducing Heme Oxygenase-1. Circulation Research, 112(2), 278-288. [More Information]
  • van der Vorst, E., Vanags, L., Dunn, L., Prosser, H., Rye, K., Bursill, C. (2013). High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells. The FASEB Journal, 27(4), 1413-1425. [More Information]
  • Mulay, V., Wood, P., Manetsch, M., Darabi, M., Cairns, R., Hoque, M., Chan, K., Reverter, M., Alvarez-Guaita, A., Rye, K., Grewal, T., et al (2013). Inhibition of Mitogen-Activated Protein Kinase Erk1/2 Promotes Protein Degradation of ATP Binding Cassette Transporters A1 and G1 in CHO and HuH7 Cells. PLoS One, 8(4), 1-10. [More Information]
  • Hadfield, K., Pattison, D., Brown, B., Hou, L., Rye, K., Davies, M., Hawkins, C. (2013). Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCI). The Biochemical Journal, 449(2), 531-542. [More Information]
  • Ong, K., Allison, M., Cheung, B., Wu, B., Barter, P., Rye, K. (2013). Trends in C-Reactive Protein Levels in US Adults From 1999 to 2010. American Journal of Epidemiology, 177(12), 1430-1442. [More Information]

2012

  • Borthwick, F., Warnakula, S., Mangat, R., Uwiera, R., Russell, J., Kelly, S., Lee, C., Hryshko, L., Mamo, J., Rye, K., et al (2012). ApoA-1 infusion reduces arterial cholesterol and myocardial lesions in a rat model of cardiac dysfunction and insulin resistance. Atherosclerosis, 222(2), 402-408. [More Information]
  • Barter, P., Rye, K. (2012). Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. Journal of Lipid Research, 53(9), 1755-1766. [More Information]
  • Gao, X., Gu, H., Li, G., Rye, K., Zhang, D. (2012). Identification of an amino acid residue in ATP-binding cassette transport G1 critical for mediating cholesterol efflux. Biochimica et Biophysica Acta (Molecular and Cell Biology of Lipids), 1821 (3), 552-559. [More Information]
  • Ong, K., Rye, K., O'Connell, R., Jenkins, A., Brown, C., Xu, A., Sullivan, D., Barter, P., Keech, A. (2012). Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 97(12), 4701-4708. [More Information]
  • Wu, B., Chen, K., Barter, P., Rye, K. (2012). Niacin Inhibits Vascular Inflammation via the Induction of Heme Oxygenase-1. Circulation, 125(1), 150-158. [More Information]
  • Tso, C., Rye, K., Barter, P. (2012). Phenotypic and functional changes in blood monocytes following adherence to endothelium. PLoS One, 7(5), 1-11. [More Information]
  • Huijgen, R., Boekholdt, S., Arsenault, B., Bao, W., Davaine, J., Tabet, F., Petrides, F., Rye, K., DeMicco, D., Barter, P., et al (2012). Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial: A Nested Case-Control Study. Journal of the American College of Cardiology, 59(20), 1778-1784. [More Information]
  • Rye, K., Barter, P. (2012). Predictive value of different HDL particles for the protection against or risk of coronary heart disease. Biochimica et Biophysica Acta (Molecular and Cell Biology of Lipids), 1821 (3), 473-480. [More Information]
  • Barter, P., Rye, K., Beltangady, M., Ports, W., Duggan, W., Boekholdt, S., DeMicco, D., Kastelein, J., Shear, C. (2012). Relationship between atorvastatin dose and the harm caused by torcetrapib. Journal of Lipid Research, 53(11), 2436-2442. [More Information]
  • Zhang, L., Yan, F., Zhang, S., Lei, D., Charles, M., Cavigiolio, G., Oda, M., Krauss, R., Weisgraber, K., Rye, K., et al (2012). Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nature Chemical Biology, 8(4), 342-349. [More Information]
  • Drew, B., Rye, K., Duffy, S., Barter, P., Kingwell, B. (2012). The emerging role of HDL in glucose metabolism. Nature Reviews Endocrinology, 8(4), 237-245. [More Information]
  • Rye, K., Barter, P. (2012). The inhibition of cholesteryl ester transfer protein: a long and winding road. Journal of Lipid Research, 53(6), 1039-1041. [More Information]

2011

  • Ong, K., Wu, B., Cheung, B., Barter, P., Rye, K. (2011). Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999-2008. Atherosclerosis, 219(2), 728-733. [More Information]
  • Barter, P., Rye, K. (2011). Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now? Trends In Pharmacological Sciences, 32(12), 694-699. [More Information]
  • Barter, P., Rye, K., Tardif, J., Waters, D., Boekholdt, S., Breazna, A., Kastelein, J. (2011). Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial. Circulation, 124(5), 555-562. [More Information]
  • Ong, K., Tso, A., Xu, A., Law, L., Li, M., Wat, N., Rye, K., Lam, T., Cheung, B., Lam, K. (2011). Evaluation of the combined use of adiponectin and C-reactive protein levels as biomarkers for predicting the deterioration in glycaemia after a median of 5.4 years. Diabetologia: clinical and experimental diabetes and metabolism, 54(10), 2552-2560. [More Information]
  • Reimers, G., Jackson, C., Rickards, J., Chan, P., Cohn, J., Rye, K., Barter, P., Rodgers, K. (2011). Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I. Cardiovascular Research, 91(1), 37-44. [More Information]
  • Elliott, D., Tsoi, K., Holinkova, S., Chan, S., Kim, W., Halliday, G., Rye, K., Garner, B. (2011). Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiology of Aging: age-related phenomena, neurodegeneration and neuropathology, 32(2), 257-271. [More Information]
  • Tabet, F., Lambert, G., Torres, L., Hou, L., Sotirchos, I., Touyz, R., Jenkins, A., Barter, P., Rye, K. (2011). Lipid-Free Apolipoprotein A-I and Discoidal Reconstituted High-Density Lipoproteins Differentially Inhibit Glucose-Induced Oxidative Stress in Human Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(5), 1192-1200. [More Information]
  • Zhang, L., Song, J., Cavigiolio, G., Ishida, B., Zhang, S., Kane, J., Weisgraber, K., Oda, M., Rye, K., Pownall, H., et al (2011). Morphology and structure of lipoproteins revealed by an optimized negative-staining protocol of electron microscopy. Journal of Lipid Research, 52(1), 175-184. [More Information]
  • Kitajima, K., Miura, S., Yamauchi, T., Uehara, Y., Kiya, Y., Rye, K., Kadowaki, T., Saku, K. (2011). Possibility of increasing cholesterol efflux by adiponectin and its receptors through the ATP binding cassette transporter A1 in HEK293T cells. Biochemical and Biophysical Research Communications, 411(2), 305-311. [More Information]
  • Wood, P., Mulay, V., Darabi, M., Chan, K., Heeren, J., Pol, A., Lambert, G., Rye, K., Enrich, C., Grewal, T. (2011). RAS/Mitogen-activated Protein Kinase (MAPK) Signalling Modulates Protein Stability and Cell Surface Expression of Scavenger Receptor SR-BI. Journal of Biological Chemistry, 286(26), 23077-23092. [More Information]
  • Di Bartolo, B., Nicholls, S., Bao, B., Rye, K., Heather, A., Barter, P., Bursill, C. (2011). The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Atherosclerosis, 217(2), 395-400. [More Information]
  • Di Bartolo, B., Vanags, L., Tan, J., Bao, B., Rye, K., Barter, P., Bursill, C. (2011). The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit. Lipids in Health and Disease, 10(NOvember), Article no. 224-(8pp). [More Information]
  • Wu, Z., Gogonea, V., Lee, X., May, R., Pipich, V., Wagner, M., Undurti, A., Tallant, T., Baleanu-Gogonea, C., Charlton, F., Rye, K., et al (2011). The Low Resolution Structure of ApoA1 in Spherical High Density Lipoprotein Revealed by Small Angle Neutron Scattering. Journal of Biological Chemistry, 286(14), 12495-12508. [More Information]

2010

  • Patel, S., Di Bartolo, B., Nakhla, S., Heather, A., Mitchell, T., Jessup, W., Celermajer, D., Barter, P., Rye, K. (2010). Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis, 212(2), 392-397. [More Information]
  • Fryirs, M., Barter, P., Appavoo, M., Tuch, B., Tabet, F., Heather, A., Rye, K. (2010). Effects of High-Density Lipoproteins on Pancreatic {beta}-Cell Insulin Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(8), 1642-1648. [More Information]
  • Wu, B., Yan, L., Charlton, F., Witting, P., Barter, P., Rye, K. (2010). Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(5), 968-975. [More Information]
  • Chan, D., Hamilton, S., Rye, K., Chew, G., Jenkins, A., Lambert, G., Watts, G. (2010). Fenofibrate Concomitantly Decreases Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Very-Low-Density Lipoprotein Particle Concentrations in Statin-treated Type 2 Diabetic Patients. Diabetes, Obesity and Metabolism, 12(9), 752-756. [More Information]
  • Bursill, C., Castro, M., Beattie, D., Nakhla, S., van der Vorst, E., Heather, A., Barter, P., Rye, K. (2010). High-Density Lipoproteins Suppress Chemokines and Chemokine Receptors In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(9), 1773-1778. [More Information]
  • Nobecourt, E., Tabet, F., Lambert, G., Puranik, R., Bao, B., Yan, L., Davies, M., Brown, B., Jenkins, A., Dusting, G., Barter, P., Rye, K., et al (2010). Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(4), 766-772. [More Information]
  • Imaizumi, S., Kiya, Y., Miura, S., Zhang, B., Matsuo, Y., Uehara, Y., Rye, K., Saku, K. (2010). Pharmacological intervention using reconstituted high-density lipoprotein changes in the lipid profile in spontaneously hypersensitive rats. Clinical and Experimental Hypertension, 32(3), 202-208. [More Information]
  • de Souza, J., Vindis, C., Negre-Salvayre, A., Rye, K., Couturier, M., Therond, P., Chantepie, S., Salvayre, R., Chapman, M., Kontush, A. (2010). Small, dense HDL3 particles attenuates apoptosis in endothelial cells: Pivotal role of apolipoprotein A-I. Journal of Cellular and Molecular Medicine, 14(3), 608-620. [More Information]
  • Tabet, F., Remaley, A., Segaliny, A., Millet, J., Yan, L., Nakhla, S., Barter, P., Rye, K., Lambert, G. (2010). The 5A Apolipoprotein A-I Mimetic Peptide Displays Antiinflammatory and Antioxidant Properties In Vivo and In Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(2), 246-252. [More Information]

2009

  • Patel, S., Puranik, R., Nakhla, S., Lundmand, P., Stocker, R., Wang, X., Lambert, G., Rye, K., Barter, P., Nicholls, S., Celermajer, D. (2009). Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis, 204(2), 424-428. [More Information]
  • Fryirs, M., Barter, P., Rye, K. (2009). Cholesterol metabolism and pancreatic B-cell function. Current Opinion in Lipidology, 20(3), 159-164. [More Information]
  • Barter, P., Rye, K. (2009). High-density lipoprotein as a therapeutic target. In Tonkin, Andrew (Eds.), Therepeutic Strategies: Lipid Disorders, (pp. 29-42). United Kingdom: Clinical Publishing, Oxford.
  • Tabet, F., Rye, K. (2009). High-density lipoproteins, inflammation and oxidative stress. Clinical Science, 116(2), 87-98. [More Information]
  • Lambert, G., Charlton, F., Rye, K., Piper, D. (2009). Molecular basis of PCSK9 function. Atherosclerosis, 203, 1-7. [More Information]
  • Chan, D., Lambert, G., Barrett, P., Rye, K., Ooi, E., Watts, G. (2009). Plasma proprotein convertase subtilisin/kexin type 9: A marker of LDL apolipoprotein B-100 catabolism? Clinical Chemistry (Washington, DC), 55(11), 2049-2052. [More Information]
  • Kiya, Y., Miura, S., Imaizumi, S., Uehara, Y., Matsuo, Y., Abe, S., Jimi, S., Urata, H., Rye, K., Saku, K. (2009). Reconstituted high-density lipoprotein attenuates postinfarction left ventricular remodeling in rats. Atherosclerosis, 203(1), 137-144. [More Information]
  • Patel, S., Drew, B., Nakhla, S., Duffy, S., Murphy, A., Barter, P., Rye, K., Chin-Dusting, J., Hoang, A., Sviridov, D., Celermajer, D., et al (2009). Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. Journal of the American College of Cardiology, 53(11), 962-971. [More Information]
  • Peshavariya, H., Dusting, G., Di Bartolo, B., Rye, K., Barter, P., Jiang, F. (2009). Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free Radical Research, 43(8), 772-782. [More Information]
  • Chan, D., Watts, G., Ooi, E., Rye, K., Ji, J., Johnson, A., Barrett, P. (2009). Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome. Diabetes Care, 32(11), 2111-2113. [More Information]
  • McGrath, K., Li, X., Puranik, R., Liong, E., Tan, J., Dy, V., Di Bartolo, B., Barter, P., Rye, K., Heather, A. (2009). Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 877-882. [More Information]
  • Rye, K., Bursill, C., Lambert, G., Tabet, F., Barter, P. (2009). The metabolism and anti-atherogenic properties of HDL. Journal of Lipid Research, 50(Supplement), S195-S200. [More Information]

2008

  • Kim, W., Elliott, D., Kockx, M., Kritharides, L., Rye, K., Jans, D., Garner, B. (2008). Analysis of apolipoprotein E nuclear localization using green fluorescent protein and biotinylation approaches. Biochemical Journal, 409(3), 701-709. [More Information]
  • Rye, K., Barter, P. (2008). Antiinflammatory Actions of HDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(11), 1890-1891. [More Information]
  • Tabet, F., Barter, P., Rye, K. (2008). Apolipoprotein A-I and Reconstituted High-Density Lipoproteins Inhibit NADPH Oxidase Activation and Expression and Increase Superoxide Dismutase Levels in Human Macrophages in High Glucose Conditions. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(6), e-87.
  • Chan, S., Kim, W., Kwok, J., Hill, A., Cappai, R., Rye, K., Garner, B. (2008). ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. Journal of Neurochemistry, 106(2), 793-804. [More Information]
  • Nobécourt, E., Zeng, J., Davies, M., Bronwyn, B., Yadav, S., Barter, P., Rye, K. (2008). Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I. Diabetologia: clinical and experimental diabetes and metabolism, 51(6), 1008-1017. [More Information]
  • Homer, V., Marais, A., Charlton, F., Laurie, A., Hurndell, N., Scott, R., Mangili, F., Sullivan, D., Barter, P., Rye, K., et al (2008). Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis, 196(2), 659-666. [More Information]
  • Di Bartolo, B., Bao, B., Rye, K., Nicholls, S., Barter, P. (2008). In Vivo Properties of a Novel Apolipoprotein A-1 Mimetic Peptide. Journal of the American College of Cardiology, 51(10), A283.
  • Barter, P., Rye, K. (2008). Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome? Arteriosclerosis, Thrombosis, and Vascular Biology, 28(1), 39-46. [More Information]
  • Puranik, R., Bao, B., Nobecourt, E., Nicholls, S., Dusting, G., Barter, P., Celermajer, D., Rye, K. (2008). Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis, 196(1), 240-247. [More Information]
  • Glaros, E., Kim, W., Quinn, C., Jessup, W., Rye, K., Garner, B. (2008). Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. Journal of Lipid Research, 49(2), 324-331. [More Information]
  • Lambert, G., Ancellin, N., Charlton, F., Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D., Cohn, J., Rye, K., Barter, P. (2008). Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment. Clinical Chemistry (Washington, DC), 54(6), 1038-1045. [More Information]
  • Uehara, Y., Tsuboi, Y., Zhang, B., Miura, S., Baba, Y., Higuchi, M., Yamada, T., Rye, K., Saku, K. (2008). POPC/apoA-I discs as a potent lipoprotein modulator in Tangier disease. Atherosclerosis, 197(1), 283-289. [More Information]
  • Glaros, E., Kim, W., Rye, K., Shayman, J., Garner, B. (2008). Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice. Journal of Lipid Research, 49(8), 1677-1681. [More Information]
  • Settasatian, N., Barter, P., Rye, K. (2008). Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein. Journal of Lipid Research, 49(1), 115-126. [More Information]
  • D. Silva, R., Huang, R., Morris, J., Fang, J., Gracheva, E., Ren, G., Kontush, A., Jerome, W., Rye, K., Davidson, W. (2008). Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 105(34), 12176-12181.

2007

  • Patel, S., Drew, B., Duffy, S., Nahkla, S., Rye, K., Barter, P., Celermajer, D., Kingwell, B. (2007). Abstract 1047: Infusion of Reconstituted High Density Lipoproteins Into Humans Enhances the In Vitro Anti-Inflammatory Capacity of the High Density Lipoprotein Fraction. Circulation, 116, II_209.
  • Theodore, W., Watts, G., Barrett, P., Rye, K., Chan, D. (2007). Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care, 30(11), 2945-2950. [More Information]
  • Zhang, B., Uehara, Y., Hida, S., Miura, S., Rainwater, D., Segawa, M., Kumagai, K., Rye, K., Saku, K. (2007). Effects of reconstituted HDL on charge-based LDL subfractions as characterized by capillary isotachophoresis. Journal of Lipid Research, 48, 1175-1189. [More Information]
  • Barter, P., Rye, K. (2007). HDL and Atherosclerosis. In Christopher J Fielding (Eds.), High Density Lipoproteins: From Basic Biology to Clinical Aspects, (pp. 491-505). Germany: Wiley - V C H Verlag GmbH & Co. KGaA.
  • Barter, P., Rye, K. (2007). HDL structure and metabolism: Its regulation by cell membrane receptors. In C J Packard (Eds.), The Year in Lipid Disorders. Volume 1, (pp. 93-112). United Kingdom: Clinical Publishing, Oxford.
  • Siggins, S., Rye, K., Olkkonen, V., Jauhiainen, M., Ehnholm, C. (2007). Human plasma phospholipid transfer protein, PLTP. Structural and functional features. In Christopher J Fielding (Eds.), High Density Lipoproteins: From Basic Biology to Clinical Aspects, (pp. 183-205). Germany: Wiley - V C H Verlag GmbH & Co. KGaA.
  • Homer, V., Marais, A., Laurie, A., Charlton, F., Sullivan, D., Barter, P., Rye, K., George, P., Lambert, G. (2007). Identification and Molecular Characterization of New PCSK9 Missense Mutations Associated with Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(6), e-122.
  • Glaros, E., Kim, W., Wu, B., Suarna, C., Quinn, C., Rye, K., Stocker, R., Jessup, W., Garner, B. (2007). Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochemical Pharmacology, 73(9), 1340-1346. [More Information]
  • Skropeta, D., Settasatian, C., McMahon, M., Shearston, K., Caiazza, D., McGrath, K., Jin, W., Rader, D., Barter, P., Rye, K. (2007). N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins. Journal of Lipid Research, 48(9), 2047-2057. [More Information]
  • Barter, P., Puranik, R., Rye, K. (2007). New insights into the role of HDL as an antiinflammatory agent in the prevention of cardiovascular disease. Current Cardiology Reports, 9(6), 493-498. [More Information]
  • Matsuo, Y., Miura, S., Kawamura, A., Uehara, Y., Rye, K., Saku, K. (2007). Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation. Atherosclerosis, 194, 159-168. [More Information]
  • Sumi, M., Sata, M., Miura, S., Rye, K., Toya, N., Kanaoka, Y., Yanaga, K., Ohki, T., Saku, K., Nagai, R. (2007). Reconstituted High-Density Lipoprotein Stimulates Differentiation of Endothelial Progenitor Cells and Enhances Ischemia-Induced Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(4), 813-818. [More Information]
  • Nobecourt, E., Davies, M., Brown, B., Curtiss, L., Bonnet, D., Charlton, F., Januszewski, A., Jenkins, A., Barter, P., Rye, K. (2007). The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia: clinical and experimental diabetes and metabolism, 50(3), 643-653. [More Information]

2006

  • Puranik, R., Bao, B., Celermajer, D., Rye, K., Barter, P., Nicholls, S., Nobecourt, E. (2006). A single infusion of lipid free apo A1 can rescue vascular inflammation. Atherosclerosis Supplements, 7, 153.
  • Gelissen, I., Harris, M., Quinn, C., Rye, K., Brown, A., Kockx, M., Cartland, S., Packianathan, M., Kritharides, L., Jessup, W. (2006). ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(3), 534-540. [More Information]
  • Puranik, R., Nobecourt, E., Bao, B., Davies, M., Barter, P., Celermajer, D., Rye, K. (2006). Abstract 1355: The Impact of Glycation on the Anti-inflammatory Properties of High Density Lipoproteins in vivo. Circulation, 114, II-257-II-258.
  • Barter, P., Rye, K. (2006). Are we lowering LDL cholesterol sufficiently? Nature Clinical Practice Cardiovascular Medicine, 3(6), 290-291. [More Information]
  • Barter, P., Rye, K. (2006). Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism? Circulation, 113(12), 1553-1555.
  • Teo, K., Nicholls, S., Kee, P., Rye, K., Barter, P. (2006). Combination high-density lipoprotein infusion and atorvastatin significantly reduces experimental atherosclerosis compared to either therapy alone: serial analysis with high-resolution MRI. European Heart Journal, 27(Suppl 1), 973-974.
  • Nicholls, S., Lundman, P., Harmer, J., Cutri, B., Griffiths, K., Rye, K., Barter, P., Celermajer, D. (2006). Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. Journal of the American College of Cardiology, 48(4), 715-720. [More Information]
  • Zhang, B., Katafuchi, R., Arishima, H., Matsunaga, A., Rye, K., Saku, K. (2006). Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis. Clinica Chimica Acta, 373(1-2), 55-61.
  • Nobecourt, E., Puranik, R., Bao, B., Davies, M., Barter, P., Rye, K. (2006). Evidence that glycation of apolipoprotein. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Taylor, J., Rye, K., Sloane, T., Gaus, K., Ruberu, K., Jessup, W., Kritharides, L. (2006). Exogenous apolipoprotein A-I promotes faecal sterol excretion in hypercholesterolemic rabbits. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Hime, N., Drew, K., Wee, K., Barter, P., Rye, K. (2006). Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit. Journal of Lipid Research, 47(1), 115-122. [More Information]
  • Rye, K., Barter, P., Bao, B. (2006). HDL and the inhibition of inflammation in vivo. Atherosclerosis Supplements, 7, 152.
  • Ji, J., Watts, G., Johnson, A., Chan, D., Ooi, E., Rye, K., Serone, A., Barrett, P. (2006). High-density lipoprotein (HDL) transport in the metabolic syndrome: Application of a new model for HDL particle kinetics. Journal of Clinical Endocrinology and Metabolism, 91(3), 973-979. [More Information]
  • Tso, C., Martinic, G., Fan, W., Rogers, C., Rye, K., Barter, P. (2006). High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(5), 1144-1149. [More Information]
  • Barter, P., Rye, K. (2006). Homocysteine and Cardiovascular Disease: Is HDL the Link? Circulation Research, 99(6), 565-566.
  • Rentero, C., Evans, R., Wood, P., Tebar, F., Vila de Muga, S., Cubells, L., de Diego, I., Hayes, T., Hughes, W., Pol, A., Rye, K., Grewal, T., et al (2006). Inhibition of H-Ras and MAPK is compensated by PKC-dependent pathways in annexin A6 expressing cells. Cellular Signalling, 18(7), 1006-1016. [More Information]
  • Ooi, E., Watts, G., Ji, J., Rye, K., Johnson, A., Chan, D., Barrett, P. (2006). Plasma phospholipid transfer protein activity, a determinant of HDL kinetics in vivo. Clinical Endocrinology, 65(6), 752-759.
  • Rye, K., Bright, R., Psaltis, M., Barter, P. (2006). Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E. Journal of Lipid Research, 47(5), 1025-1036. [More Information]
  • Barter, P., Rye, K. (2006). Relationship between the concentration and antiatherogenic activity of high-density lipoproteins. Current Opinion in Lipidology, 17(4), 399-403. [More Information]
  • Watts, G., Ji, J., Chan, D., Ooi, E., Johnson, A., Rye, K., Barrett, P. (2006). Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. Clinical Science, 111(3), 193-199.
  • Kim, W., Rahmanto, A., Kamili, A., Rye, K., Guillemin, G., Gelissen, I., Jessup, W., Hill, A., Garner, B. (2006). Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein-E discs and suppression of amyloid-beta peptide generation. Journal of Biological Chemistry, 282(5), 2851-2861. [More Information]
  • Barter, P., Rye, K. (2006). The Argument Against the Appropriateness of Over-the-Counter Statins. Circulation, 114(12), 1315-1320. [More Information]
  • Rye, K., Nobecourt, E., Puranik, R., Bao, B., Barter, P. (2006). The impact of diabetes on the anti-inflammatory properties of high density lipoproteins in vivo. European Heart Journal, 27(Suppl 1), 520.
  • Barter, P., Rye, K. (2006). The rationale for using apoA-I as a clinical marker of cardiovascular risk. Journal of Internal Medicine, 259(5), 447-454. [More Information]
  • Curtiss, L., Valenta, D., Hime, N., Rye, K. (2006). What is so special about apolipoprotein AI in reverse cholesterol transport? Arteriosclerosis, Thrombosis, and Vascular Biology, 26(1), 12-19.

2005

  • Grewal, T., Evans, R., Rentero, C., Tebar, F., Cubells, L., de Diego, I., Kirchhoff, M., Hughes, W., Heeren, J., Rye, K., et al (2005). Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity. Oncogene, 24(38), 5809-5820. [More Information]
  • Zhang, B., Miura, S., Fan, P., Kumagai, K., Takeuchi, K., Uehara, Y., McMahon, M., Rye, K., Saku, K. (2005). ApoA-I/phosphatidylcholine discs remodels fast-migrating HDL into slow-migrating HDL as characterized by capillary isotachophoresis. Atherosclerosis, 188(1), 95-101. [More Information]
  • Janis, M., Metso, J., Lankinen, H., Strandin, T., Olkkonen, V., Rye, K., Jauhiainen, M., Ehnholm, C. (2005). Apolipoprotein E activates the low-activity form of human phospholipid transfer protein. Biochemical and Biophysical Research Communications, 331(1), 333-340. [More Information]
  • Nicholls, S., Celermajer, D., Rye, K., Barter, P., Griffiths, K., Cutri, B., Harmer, J., Lundman, P. (2005). Consumption of saturated fat impairs endothelial function and the antiinflammatory properties of high-density lipoproteins. Circulation, 112(17), U43.
  • Kee, P., Caiazza, D., Rye, K., Barrett, P., Morehouse, L., Barter, P. (2005). Effect of Inhibiting Cholesteryl Ester Transfer Protein on the Kinetics of High-Density Lipoprotein Cholesteryl Ester Transport in Plasma: In Vivo Studies in Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(4), 884-890. [More Information]
  • Jahangiri, A., Rader, D., Marchadier, D., Curtiss, L., Bonnet, D., Rye, K. (2005). Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. Journal of Lipid Research, 46(5), 896-903.
  • Nicholls, S., Rye, K., Barter, P. (2005). High-density lipoproteins as therapeutic targets. Current Opinion in Lipidology, 16(3), 345-349. [More Information]
  • Nicholls, S., Cutri, B., Worthley, S., Kee, P., Rye, K., Bao, B., Barter, P. (2005). Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(11), 2416-2421. [More Information]
  • Raftery, M., Campbell, R., Glaros, E., Rye, K., Halliday, G., Jessup, W., Garner, B. (2005). Phosphorylation of Apolipoprotein-E at an Atypical Protein Kinase CK2 PSD/E Site in Vitro. Biochemistry, 44(19), 7346-7353. [More Information]
  • Nicholls, S., Dusting, G., Cutri, B., Bao, B., Drummond, G., Rye, K., Barter, P. (2005). Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation, 111(12), 1543-1550. [More Information]
  • Settasatian, N., Barter, P., Rye, K. (2005). The Influence of Apolipoprotein E Isoforms on High Density Lipoprotein Remodelling by Phospholipid Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(5), E-90.
  • Settasatian, C., van der Meer, A., Rader, D., Barter, P., Rye, K. (2005). The Role of the Beta5 Loop of Endothelial Lipase in the Hydrolysis of Reconstituted High-Density Lipoprotein Phospholipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(5), E-76.

2004

  • Barter, P., Nicholls, S., Rye, K., Anantharamaiah, G., Navab, M., Fogelman, A. (2004). Antiinflammatory Properties Of HDL. Circulation Research, 95(8), 764-772. [More Information]
  • Kockx, M., Rye, K., Gaus, K., Quinn, C., Wright, J., Sloane, T., Sviridov, D., Sullivan, D., Fu, Y., Burnett, J., Kritharides, L., et al (2004). Apolipoprotein A-I-Stimulated Apolipoprotein E Secretion From Human Macrophages Is Independent Of Cholesterol Efflux. Journal of Biological Chemistry, 279(25), 25966-25977.
  • Hime, N., Drew, K., Hahn, C., Barter, P., Rye, K. (2004). Apolipoprotein E Enhances Hepatic Lipase-Mediated Hydrolysis of Reconstituted High-Density Lipoprotein Phospholipid and Triacylglycerol in an Isoform-Dependent Manner. Biochemistry, 43(38), 12306-12314.
  • Hime, N., Drew, K., Hahn, C., Barter, P., Rye, K. (2004). Apolipoprotein E Enhances Hepatic Lipase-Mediated Hydrolysis Of Reconstituted High-Density Lipoprotein Phospholipid And Triacylglycerol In An Isoform-Dependent Manner. Biochemistry, 43(38), 12306-12314.
  • Caiazza, D., Jahangiri, A., Rader, D., Marchadier, D., Rye, K. (2004). Apolipoproteins Regulate The Kinetics Of Endothelial Lipase-Mediated Hydrolysis Of Phospholipids In Reconstituted High-Density Lipoproteins. Biochemistry, 43(37), 11898-11905.
  • Rye, K., Barter, P. (2004). Formation And Metabolism Of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(3), 421-428. [More Information]
  • Wadham, C., Albanese, N., Roberts, J., Wang, L., Bagley, C., Gamble, J., Rye, K., Barter, P., Vadas, M., Xia, P. (2004). High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity. Circulation, 109(17), 2116-2122. [More Information]
  • Heeren, J., Grewal, T., Laatsch, A., Becker, N., Rinninger, F., Rye, K., Beisiegel, U. (2004). Impaired Recycling of Apolipoprotein E4 Is Associated with Intracellular Cholesterol Accumulation. Journal of Biological Chemistry, 279(53), 55483-55492. [More Information]
  • Hime, N., Drew, K., Barter, P., Rye, K. (2004). In Vivo Formation of High-Density Lipoproteins Containing Both Apolipoprotein A-I and Apolipoprotein A-II in the Rabbit. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(5), E-104.

2003

  • Duong, M., Psaltis, M., Rader, D., Marchadier, D., Barter, P., Rye, K. (2003). Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids. Biochemistry, 42(46), 13778-13785. [More Information]

2002

  • Rye, K., Duong, M., Psaltis, M., Curtiss, L., Bonnet, D., Stocker, R., Barter, P. (2002). Evidence that phospholipids play a key role in pre-β apoA-I formation and high density lipoprotein remodeling. Biochemistry, 41(41), 12538-12545.

2000

  • Panzenboeck, U., Kritharides, L., Raftery, M., Rye, K., Stocker, R. (2000). Oxidation of methionine residues to methionine sulfoxides enhances rather than decreases potential anti-atherogenic properties of apolipoprotein. Journal of Biological Chemistry, 275, 19536-19544.

To update your profile click here. For support on your academic profile contact .